Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients

Background: Spinal muscular atrophy type 1 (SMA1) is a devastating genetic disease for which gene-replacement therapy may bring substantial survival and quality of life benefits. Objective: This study investigated the cost-effectiveness of onasemnogene abeparvovec (AVXS-101) gene-replacement therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Malone, Daniel C., Dean, Rebecca, Arjunji, Ramesh, Jensen, Ivar, Cyr, Phil, Miller, Beckley, Maru, Benit, Sproule, Douglas M., Feltner, Douglas E., Dabbous, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508058/
https://www.ncbi.nlm.nih.gov/pubmed/31105909
http://dx.doi.org/10.1080/20016689.2019.1601484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508058/
https://www.ncbi.nlm.nih.gov/pubmed/31105909
http://dx.doi.org/10.1080/20016689.2019.1601484

Ejemplares similares